跳至主要内容
临床试验/JPRN-UMIN000053038
JPRN-UMIN000053038招募中Unknown

Elucidation of the role of Receptor activator of nuclear factor kappa-B (RANK)/RANK ligand (RANKL) signals in the onset and progression of primary biliary cholangitis - Elucidation of the role of Receptor activator of nuclear factor kappa-B (RANK)/RANK ligand (RANKL) signals in the onset and progression of primary biliary cholangitis

Tokai University School of Medicine0 个研究点目标入组 40 人开始时间: 2023年12月8日最近更新:
适应症

试验速览

阶段
Unknown
状态
招募中
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 89years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • Hypocalcemia (corrected serum calcium level less than 8.4mg/dl) Severe renal dysfunction (eGFR 35 < mL/min/1.73m2) Child-Pugh classification grade B or C Total bilirubin level is 5 mg/dl or more Concomitant with ascites Complicated by poorly controlled hepatic encephalopathy Complicated by uncontrolled malignant tumor Requires dental treatment Taking corticosteroids Patients with a history of hypersensitivity to denosumab

研究者

相似试验

进行中(未招募)
不适用
Estudio VITAL- Estudio del activador del receptor de la vitamina D selectivo (Paricalcitol) para la reducción de la albúmina: Estudio multicéntrico de fase II, prospectivo aleatorizado, a doble ciego y controlado mediante placebo, para evaluar la seguridad y eficacia de las cápsulas de paricalcitol en la reducción de la albuminuria en pacientes con diabetes de tipo 2 que presentan nefropatía y que están siendo tratados actualmente con inhibidores del sistema renina-angiotensina.VITAL Study-Selective VITamin D Receptor Activator (Paricalcitol) for Albuminuria Lowering Study: A Phase 2, Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects who are Currently Being Treated with Renin-angiotensin Sytem Inhibitors. - Not availableefropatía diabética Tipo 2.Type 2 diabetic nephropathy.MedDRA version: 9.1Level: LLTClassification code 10064848Term: Chronic kidney disease
EUCTR2006-001363-31-ESAbbott GmbH & Co KG258
已完成
不适用
Potential roles of neurotransmitter receptors and mitochondria in the pathophysiology of autism spectrum disorder: A PET studyAutism spectrum disorder
JPRN-UMIN000029183Hamamatsu University school of medicine47
已完成
不适用
Expression and functional analyses of immunoreceptors on human blood cells
JPRN-UMIN000012333niversity of Tsukuba300
撤回
不适用
RRR Study: study on the role of inhibitory receptors in respiratory syncytial virus (RSV) bronchiolitisbronchiolitis
NL-OMON34523niversitair Medisch Centrum Utrecht
已完成
不适用
Effects of the norepinephrine reuptake inhibitor reboxetine on the exploitation-exploration trade-offgeen aandoeningen, onderzoek op gezonde vrijwilligersnormal explorative behaviour
NL-OMON31488Centre for Human Drug Research48